Company profile
Definium Therapeutics, Inc. -
Pipeline2 assets
- DT120 ODTDT120 / serotonin receptors / Orally disintegrating tablet formulation of lysergide (LSD) D-tartrate / Psychiatry / brain healthGeneralized anxiety disorderPhase 3Two Phase 3 registrational trials ongoing/evaluating efficacy and safetyU.S.EuropeMajor depressive disorderPhase 3Emerge Phase 3 ongoing; Ascend Phase 3 expected to initiate mid-2026U.S.
- DT402DT402 / serotonergic system / R-enantiomer of MDMA (R(-)-MDMA) / Neurodevelopmental disordersAutism spectrum disorderPhase 2aPhase 2a study initiated after completion of Phase 1 single-ascending dose study
Latest news15 items
All newsDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Trial Start • Phase 3Trial initiation Tue, May 12, 2026, 7:00 AM EDT